

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:711US

Serial No.

10/507,009

List of Patents and Publications for Applicant's

Applicant

Constantin G. Ioannides *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 7, 2004

Group:

4645 1.644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/M.D./	A1	4,433,092	02/21/84	Nemeth	524	414	09/27/82
	A2	4,554,101	11/19/85	Hopp	200	112.5	01/28/85
	A3	4,631,221	12/23/86	Disselbeck and Stahl	428	166	04/03/85
	A4	4,708,781	11/24/87	Poorten	204	180.9	10/20/86
	A5	5,194,392	03/16/93	Geysen	436	518	06/21/90
	A6	5,480,971	01/02/96	Houghton <i>et al.</i>	530	329	06/09/94
	A7	5,550,214	08/27/96	Eberlein <i>et al.</i>	530	328	02/10/94
	A8	6,075,122	06/13/00	Cheever and Disis	530	350	06/06/95
	A9	6,127,524	10/03/00	Casipit <i>et al.</i>	530	387.3	10/10/96
/M.D./	A10	6,338,945	01/15/02	Nicolette	435	7.1	12/11/91

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.D./	C1	Anderson <i>et al.</i> , "Peptide priming of cytolytic activity to her-2 epitope 369-377 in healthy individuals," <i>Clin. Cancer Res.</i> , 6:4192-4200, 2000.
/M.D./	C2	Baker <i>et al.</i> , "Conversion of a t cell antagonist into an agonist by repairing a defect in the tcr/peptide/mhc interface: implications for tcr signaling," <i>Immunity</i> , 13:475-484, 2000.
/M.D./	C3	Berman <i>et al.</i> , "The Protein Data Bank," <i>Nucleic Acids Research</i> , 28:235-242, 2000.
/M.D./	C4	Broome <i>et al.</i> , "Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal," <i>J Immunol</i> , 155:2311-7, 1995.

25459089.1

EXAMINER: /Marianne DiBrino/

DATE CONSIDERED: 10/10/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's		Applicant Constantin G. Ioannides <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: September 7, 2004	Group: T645 1644
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.D./	C5	Brutlag <i>et al.</i> , "Improved sensitivity of biological sequence database searches," <i>Comput. Appl. Biosci.</i> , 6(3):237-245, 1990.
	C6	Castilleja <i>et al.</i> , "Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope Her-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex," <i>J. Immunol.</i> , 169(7):3545-3554, 2002.
	C7	Chicz and Urban, "Analysis of mhc-presented peptides: applications in autoimmunity and vaccine development," <i>Immunol. Today</i> , 15:155-160, 1994.
	C8	Chou and Fasman, "Conformational parameters for amino acids in helical, β -sheet, and random coil regions calculated from proteins," <i>Biochemistry</i> , 13(2):211-222, 1974.
	C9	Chou and Fasman, "Prediction of protein conformation," <i>Biochemistry</i> , 13(2):222-245, 1974.
	C10	Ding <i>et al.</i> , "Four a6-tcr/peptide/hla-a2 structures that generate very different t cell signals are nearly identical," <i>Immunity</i> , 11:45, 1999.
	C11	DiSomma <i>et al.</i> , "TCR engagement regulates differential responsiveness of human memory t cells to fas (cd95)-mediated apoptosis," <i>J. Immunol.</i> , 162:3851, 1999.
	C12	Eberl <i>et al.</i> , "MHC class I H-2Kd-restricted antigenic peptides: additional constraints for the binding motif," <i>Int. Immunol.</i> , 5(11):1489-1492, 1993.
	C13	Falk <i>et al.</i> , "Allele-specific motifs revealed by sequencing of self-peptides eluted from mhc molecules," <i>Nature</i> , 351:290, 1991.
	C14	Fetrow and Bryant, "New programs for protein tertiary structure prediction," <i>Biotechnology</i> , 11(4):479-484, 1993.
	C15	Fisk <i>et al.</i> , "Mass-spectrometric analysis of naturally processed peptides recognized by ovarian tumor-associated cd8 ⁺ tcl," <i>Int. J. Oncol.</i> , 10:159-169, 1997.
	C16	Fisk <i>et al.</i> , "Identification of an immunodominant peptide of her-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic t lymphocyte lines," <i>J. Exp. Med.</i> , 181:2109-2117, 1995.
	C17	Garboczi <i>et al.</i> , "Structure of the complex between human t-cell receptor, viral peptide and hla-a2," <i>Nature</i> , 384:134-141, 1996.
/M.D./	C18	Geysen <i>et al.</i> , "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci., USA</i> , 81:3998-4002, 1984.

25459089.1

EXAMINER:

/Marianne DiBrino/

DATE CONSIDERED: 10/10/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPE609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's		Applicant Constantin G. Ioannides <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: September 7, 2004	Group: 1045 1644
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.D./	C19	Gillogly <i>et al.</i> , "Induction of immunity to her-2 by tcr directed variants of the cti epitope e75," <i>FASEB J.</i> , 14:A147.18, 2000.
	C20	Haskell-Luevano <i>et al.</i> , "β-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity," <i>J. Med. Chem.</i> , 40:2740-2749, 1997.
	C21	Hausman <i>et al.</i> , "Peptide recognition by two hla-a2/tax ₁₁₋₁₉ -specific t cell clones in relationship to their mhc/peptide/tcr crystal structures," <i>J. Immunol.</i> , 162:5389, 1999.
	C22	Houghten <i>et al.</i> , "A completely sunthetic toxoid vaccine containing <i>escheichia coli</i> heat-stable toxin and antigenic determinants of the heat-labile toxin b subunit," <i>Infection and Immunity</i> , 48:735-740, 1985.
	C23	Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids," <i>Proc. Natl. Acad. Sci., USA</i> , 82:5131-5135, 1985.
	C24	Hruby <i>et al.</i> , "Topographically designed analogues of [D-Pen, D-Pen5]enkephalin," <i>J. Med. Chem.</i> , 34:1823-1830, 1991.
	C25	Jameson and Wolf, "The antigenic index: a novel algorithm for predicting antigenic determinants," <i>Comput Appl Biosci</i> , 4(1):181-186, 1988.
	C26	Kirchhoff <i>et al.</i> , "TCR-mediated up-regulation of c-flip _{short} correlates with resistance toward cd95-mediated apoptosis by blocking death-inducing signaling complex activity," <i>J. Immunol.</i> , 165:6293, 2000.
	C27	Knutson <i>et al.</i> , "Immunization with a her-2/neu helper peptide vaccine generates her-2/neu cd8 t-cell immunity in cancer patients," <i>J. Clin. Invest.</i> , 107:477, 2001.
	C28	Krammer, "CD95's deadly mission in the immune system," <i>Nature</i> , 407:789-795, 2000.
	C29	Lee <i>et al.</i> , "Identification of activated tumor antigen-reactive cd8 ⁺ cells in healthy individuals," <i>Oncol. Reports</i> , 7:455-466, 2000.
	C30	Lu and Celis, "Use of two predictive algorithms of the world wide web for the identification of tumor-reactive t-cell epitopes," <i>Cancer Res.</i> , 60(18):5223-5227, 2000.
/M.D./	C31	Madden <i>et al.</i> , "The antigenic identity of peptide-mhc complexes: a comparison of the conformations of five viral peptides presented by hla-a2," <i>Cell</i> , 75:693-708, 1993.

25459089.1

EXAMINER: /Marianne DiBrino/

DATE CONSIDERED: 10/10/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPE609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's		Applicant Constantin G. Ioannides <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: September 7, 2004	Group: 1643 1644
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.D./	C32	Madden, "The three-dimensional structure of peptide-MHC complexes", <i>Annu Rev Immunol</i> , 13:567-622, 1995. 587-622, 1995.
	C33	Mueller <i>et al.</i> , "Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells", <i>J Immunol</i> , 156:1764-71, 1996.
	C34	Parker <i>et al.</i> , "Scheme for ranking potential hla-a2 binding peptides based on independent binding of individual peptide side-chains," <i>J. Immunol.</i> , 153:163, 1994.
	C35	Peitsch <i>et al.</i> , "Large-scale protein modelling and integration with the swiss-prot and swiss-2d page databases: the example of <i>escherichia coli</i> ," <i>Electrophoresis</i> , 18:498, 1997.
	C36	Rammensee <i>et al.</i> , "SYFPEITHI: database for mhc ligands and peptide motifs," <i>Immunogenetics</i> , 50:213-219, 1999.
	C37	Rongcun <i>et al.</i> , "Identification of new her2/neu-derived peptide epitopes that can elicit specific cti against autologous and allogeneic carcinomas and melanomas," <i>J. Immunol.</i> , 163:1037-1044, 1999.
	C38	Roy and Nicholson, "Cross-talk in cell death signaling," <i>J. Exp. Med.</i> , F21-25, 2000.
	C39	Saper <i>et al.</i> , "Refined structure of the human histocompatibility antigen hla-a2 at 2.6 Å resolution," <i>J. Mol. Biol.</i> , 219:277, 1999.
	C40	Simon <i>et al.</i> , "Modeling mhc class II molecules and their bound peptides as expressed at the cell surface," <i>Mol. Immunol.</i> , 38(9):681-687, 2002.
	C41	Spencer and Braciale, "Incomplete cd8 ⁺ t lymphocyte differentiation as a mechanism for subdominant cytotoxic t lymphocyte responses to a viral antigen," <i>J Exp Med</i> , 191:1687-1698, 2000.
	C42	Stern and Wily, "Antigenic peptide binding by class I and class II histocompatibility proteins," <i>Structure</i> , 2:245-251, 1994.
	C43	Thomas <i>et al.</i> , "The structure, metabolism and function of the carcinoembryonic antigen gene family," <i>Biochim. Biophys. Acta</i> , 1032:177, 1990.
/M.D./	C44	Van der Zee <i>et al.</i> , "Efficient mapping and characterization of a t cell epitope by the simultaneous synthesis of multiple peptides," <i>Eur. J. Immunol.</i> , 19:43-47, 1989.

25459089.1

EXAMINER: /Marianne DiBrino/

DATE CONSIDERED: 10/10/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPE609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:711US	Serial No. 10/507,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT		Applicant Constantin G. Ioannides <i>et al.</i>	
(Use several sheets if necessary)		Filing Date: September 7, 2004	Group: 1643 1644
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.D./	C45	Wallace <i>et al.</i> , "Mechanisms of adoptive immunotherapy: improved methods for <i>in vivo</i> tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells," <i>Cancer Res.</i> , 53:2358-2367, 1993.
	C46	Ward <i>et al.</i> , "Oxidant-induced s-glutathiolation inactivates protein kinase c- α (pkc- α): a potential mechanism of pkc isozyme regulation," <i>Biochemistry</i> , 39:10319, 2000.
	C47	Warner <i>et al.</i> , "Induction of HIV-specific ctl and antibody responses in mice using retroviral vector-transduced cells," <i>AIDS Res. and Human Retroviruses</i> , 7:645-655, 1991.
	C48	Weidmann <i>et al.</i> , "Relevance of the t cell receptor for immunotherapy of cancer," <i>Cancer Immunol. Immunother.</i> , 39:1-14, 1994.
	C49	Weinberger <i>et al.</i> , "Identification of human glucocorticoid receptor complementary dna clones by epitope selection," <i>Science</i> , 228:740-742, 1985.
	C50	Williams <i>et al.</i> , "A kinetic threshold between negative and positive selection based on the longevity of the t cell receptor-ligand complex," <i>J. Exp. Med.</i> , 189:1531-1544, 1999.
	C51	Wolf <i>et al.</i> , "An integrated family of amino acid sequence analysis programs," <i>Comput. Appl. Biosci.</i> , 4(1):187-191, 1988.
	C52	Zaks and Rosenberg, "Immunization with a peptide epitope (p369-377) from her-2/neu leads to peptide-specific cytotoxic t lymphocytes that fail to recognize her-2/neu+ tumors," <i>Cancer Res.</i> , 58:4902-4908, 1998.
/M.D./	C53	zum Buschenfelde <i>et al.</i> , "Generation of tumor-reactive ctl against the tumor-associated antigen her2 using retrovirally transduced dendritic cells derived from cd34 ⁺ hemopoietic progenitor cells," <i>J. Immunol.</i> , 165:4133-4140, 2000.

25459089.1

EXAMINER: /Marianne DiBrino/

DATE CONSIDERED: 10/10/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.